iX Biopharma inks agreement to distribute erectile dysfunction drug in China
Singapore
PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) for the licensing, supply and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.
In a bourse filing on Thursday, the company said that the new licensing agreement runs for an initial term of 10 years and will "allow both parties to tap on their collective strengths and capabilities to capture the vast opportunities in the China market".
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
UBS weighs synthetic risk transfer amid capital boost proposals
Oil settles higher on supply concerns in the Mid-East, economic woes subdue gains
S-Reits falter as investors weigh possibility of zero rate cuts in 2024
CapitaLand Investment posts total revenue of S$650 million for Q1
Europe: Stoxx 600 logs best day in three months as banks shine
US: Stocks rally after strong tech results